N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer, Pancreatic Cancer
Both
Lung Cancer, Pancreatic Cancer
Trial Information
Inclusion Criteria:
- patients with NSC type of lung cancer with high expression of EGFR who are candidates
for erlotinib as second / third line of treatment;
- patients with advanced pancreatic tumor who are candidates for complex gemcitabine
and erlotinib treatment.
Exclusion Criteria:
- lack of histological diagnosis;
- not a candidate for erlotinib;
- pregnancy.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Measure of extent and intensity ( by standardized uptake value - SUV) of C11-Erlotinib accumulation by tumors and metastasis before and after treatment
Authority:
Israel: Institutional Review Board
Study ID:
0365-12-HMO
NCT ID:
NCT01717807
Start Date:
April 2013
Completion Date:
Related Keywords:
- Lung Cancer
- Pancreatic Cancer
- epithelial growth factor receptors
- lung cancer
- advanced tumor of pancrease
- erlotinib
- C11-Erlotinib PET/CT
- Lung Neoplasms
- Pancreatic Neoplasms
Name | Location |
|---|
